Hydrogen Water Shows Promise for Chronic Fatigue Syndrome Treatment
- Authors
- Fred Friedberg, Tyler W LeBaron
- Journal
- Frontiers in Medicine
- Year
- 2026
- DOI
- 10.3389/fmed.2026.1760210
- Study Type
- clinical
- Peer Reviewed
- Yes
- Country
- United States
- Health Condition
- Myalgic Encephalomyelitis
- Body System
- Nervous System
TL;DR
Scientists found that drinking hydrogen-rich water might help people with ME/CFS (a disease that causes extreme tiredness and body pain) by reducing inflammation and helping their cells make energy better, and early small studies show it could actually work with few side effects—but they need bigger, better studies to be sure it really helps.
Key Finding
Early clinical trials of hydrogen-rich water in ME/CFS patients showed preliminary benefits in reducing fatigue and improving physical function, though current evidence is limited by small sample sizes and reliance on self-reported outcomes rather than objective measurements.
Summary
This review examined whether hydrogen-rich water (water infused with hydrogen gas) might help people with ME/CFS (myalgic encephalomyelitis/chronic fatigue syndrome), a condition causing severe fatigue and other symptoms. Researchers looked at the biological mechanisms that might explain how hydrogen could help—such as reducing harmful molecules called free radicals and lowering inflammation—and reviewed three small clinical studies. Early results suggested hydrogen-rich water was safe and may have reduced fatigue and improved physical function in some patients, but the studies were small and relied mainly on patients reporting their own symptoms rather than objective medical tests.
Practical Takeaway
While hydrogen-rich water shows mechanistic promise for ME/CFS and early trials suggest feasibility and mild side effects, the evidence remains preliminary and based on very small studies. Anyone with ME/CFS considering this approach should know that larger, more rigorous clinical trials are needed before firm conclusions can be drawn, and this should only be pursued under medical guidance as a potential adjunctive therapy, not a primary treatment.
Abstract
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating multisystem illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and autonomic dysfunction, yet it currently lacks FDA-approved treatments. Molecular hydrogen (H2), administered primarily as hydrogen-rich water (HRW), has emerged as a potential therapeutic candidate due to its selective antioxidant effects, anti-inflammatory activity, and support of mitochondrial and cellular homeostasis. These mechanisms align with several biological abnormalities implicated in ME/CFS, including oxidative stress, chronic inflammation, and impaired energy metabolism. This narrative mini-review summarizes mechanistic evidence relevant to ME/CFS and evaluates three developmental clinical studies of HRW in this population. Although early trials are small and methodologically limited, moderate-dose HRW consumed over extended durations has demonstrated feasibility and preliminary benefits in reducing fatigue and improving physical function, with generally mild side effects. Overlapping findings in Long COVID further suggest potential applicability across related post-viral fatigue conditions. Key limitations include small sample sizes, reliance on self-report outcomes, and the absence of objective biomarkers. Future research should prioritize larger, rigorously controlled trials incorporating remote biometric and biochemical assessments to clarify mechanisms of action and identify responsive subgroups. Overall, molecular hydrogen represents a promising, low-burden adjunctive therapy warranting further investigation in ME/CFS.